Prevention of Restenosis with a Novel Radiation Catheter

Information

  • Research Project
  • 6338007
  • ApplicationId
    6338007
  • Core Project Number
    R43CA088636
  • Full Project Number
    1R43CA088636-01A1
  • Serial Number
    88636
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2001 - 22 years ago
  • Project End Date
    11/30/2002 - 21 years ago
  • Program Officer Name
    STONE, HELEN B.
  • Budget Start Date
    8/1/2001 - 22 years ago
  • Budget End Date
    11/30/2002 - 21 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/1/2001 - 22 years ago
Organizations

Prevention of Restenosis with a Novel Radiation Catheter

DESCRIPTION (PROVIDED BY APPLICANT): Angioplasty is a widely accepted non-surgical method to treat patients with coronary artery disease. It is estimated that over 700,000 angioplasty procedures were performed in 1999 worldwide. Restenosis is a common complication of angioplasty and occurs in 20-50 percent of these procedures. RadioVascular Systems (RVS) has a unique radioactive catheter that can be used to prevent restenosis after angioplasty in coronary and peripheral arteries. The RVS catheter is superior to its competition because it does not require centering or ultrasound, does not occlude blood flow, requires less radioactivity than other catheters and can be manufactured at a reasonable cost. The market for intravascular radiation is estimated to grow to over $300 million in year 2002. The experiments described in this proposal are designed to prove feasibility of a prototype catheter in an established animal model of restenosis. PROPOSED COMMERCIAL APPLICATION: The potential commercial applications of the research are immediate. The data from these experiments will be used to perfect the design of the catheter that will be used in clinical trials. Other applications of this research are related to the development of new devices for the treatment of cancer.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    102500
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:102500\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    RADIOVASCULAR SYSTEMS, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    WASHINGTON
  • Organization State
    DC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20036
  • Organization District
    UNITED STATES